Patent intelligence · US
US 6784156
Cyclosporins for the treatment of respiratory diseases
Cyclosporins for the treatment of respiratory diseases
Patent details — US 6784156
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 31, 2004
- Expiration
- Aug 26, 2024
- Applicant
- Enanta Pharmaceuticals, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K38/00, A61P, A61P11/00
Quick answer
US 6784156 (Cyclosporins for the treatment of respiratory diseases) is held by Enanta Pharmaceuticals, Inc.. Status: expired. Granted Aug 31, 2004. Expires Aug 26, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K38/00, A61P, A61P11/00, A61P11/02, A61P11/06
More from Enanta Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384753
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
granted -
US 12358921
Antiviral heterocyclic compounds
granted -
US 12297209
Benzodiazepine derivatives as RSV inhibitors
granted -
US 12281140
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
granted -
US 12268694
Combination pharmaceutical agents as RSV inhibitors
granted -
US 12264159
Functionalized heterocycles as antiviral agents
granted -
US 12162857
Antiviral compounds
granted -
US 12145941
Heterocyclic antiviral agents
granted
Frequently asked questions
What is US patent 6784156?
US 6784156 (Cyclosporins for the treatment of respiratory diseases) is held by Enanta Pharmaceuticals, Inc.. Status: expired. Granted Aug 31, 2004. Expires Aug 26, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6784156?
Enanta Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 218 pharmaceutical patents for this assignee.
When does US 6784156 expire?
Our index shows an expiration date of Aug 26, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.